HC Wainwright Predicts Pyxis Oncology Q1 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Pyxis Oncology in a note issued to investors on Monday, May 19th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology's Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.38) EPS and FY2029 earnings at $0.18 EPS.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06).

Separately, Royal Bank of Canada reissued an "outperform" rating and set a $8.00 target price on shares of Pyxis Oncology in a research report on Wednesday, March 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $9.00.

Pyxis Oncology Stock Up 2.5%

PYXS traded up $0.03 on Tuesday, reaching $1.23. 471,961 shares of the company traded hands, compared to its average volume of 741,968. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.39. The firm has a fifty day simple moving average of $1.06 and a two-hundred day simple moving average of $1.54. The company has a market cap of $76.20 million, a P/E ratio of -1.19 and a beta of 1.15.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. ProShare Advisors LLC purchased a new position in shares of Pyxis Oncology in the 4th quarter worth approximately $26,000. Caption Management LLC purchased a new stake in Pyxis Oncology during the 4th quarter worth approximately $35,000. Ameriprise Financial Inc. purchased a new stake in Pyxis Oncology during the 4th quarter worth approximately $35,000. Commonwealth Equity Services LLC grew its position in Pyxis Oncology by 61.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock worth $41,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Graham Capital Management L.P. purchased a new stake in Pyxis Oncology during the 4th quarter worth approximately $47,000. Hedge funds and other institutional investors own 39.09% of the company's stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.